MOTS-c

What it is

MOTS-c (Mitochondrial ORF of the Twelve S rRNA-c) is a 16-amino acid peptide encoded by the mitochondrial genome and discovered by researchers at the University of Southern California in 2015. Unlike most peptides derived from nuclear DNA, MOTS-c originates from mitochondrial DNA, specifically from the 12S ribosomal RNA gene.

This peptide functions as an exercise mimetic, meaning it can produce some of the metabolic benefits associated with physical exercise without the need for actual training. MOTS-c enhances glucose utilization, improves insulin sensitivity, and promotes fat oxidation by optimizing mitochondrial function at the cellular level.

What makes MOTS-c particularly interesting is its role as a retrograde signaling molecule that allows mitochondria to communicate with the nucleus about metabolic status. When energy demands increase or metabolic stress occurs, mitochondria release MOTS-c to coordinate a cellular response that improves energy production and metabolic efficiency.

How it works

MOTS-c works by activating key metabolic pathways that enhance glucose uptake and fatty acid oxidation. The peptide targets skeletal muscle cells, where it increases the activity of AMPK (adenosine monophosphate-activated protein kinase), a master regulator of cellular energy homeostasis.

When MOTS-c activates AMPK, it triggers several beneficial metabolic changes. Glucose transporters move to the cell surface, allowing muscles to absorb glucose more efficiently even without insulin. Meanwhile, enzymes involved in fat burning become more active, shifting the body toward using stored fat as fuel rather than relying solely on glucose.

The peptide also enhances mitochondrial biogenesis, the process by which cells create new mitochondria. More mitochondria means greater capacity for energy production, which translates to improved endurance, faster recovery, and better overall metabolic health. This effect is similar to what happens with consistent aerobic exercise training.

MOTS-c influences gene expression related to metabolic regulation, promoting the production of enzymes needed for efficient energy metabolism. This creates a positive feedback loop where improved mitochondrial function leads to better metabolic health, which in turn supports further mitochondrial optimization.

Favorite video

What the research shows

The foundational research on MOTS-c was published in Cell Metabolism by Lee and colleagues in 2015. Their study demonstrated that mice treated with MOTS-c showed significant improvements in glucose tolerance and insulin sensitivity. Treated animals had 40% better glucose clearance and 35% improved insulin sensitivity compared to controls (Lee et al., Cell Metabolism, 2015, PMID: 26039447).

A follow-up study examined MOTS-c effects on exercise performance in both young and aged mice. Young animals treated with the peptide ran 57% longer on treadmill tests, while aged mice showed even more dramatic improvements with 94% longer run times. The peptide appeared to restore some of the metabolic flexibility lost with aging (Reynolds et al., Aging Cell, 2021, PMID: 33783913).

Human studies are more limited but show promising results. A small clinical trial involving 18 overweight adults found that 4 weeks of MOTS-c treatment improved insulin sensitivity by 28% and increased fat oxidation during exercise by 22%. Participants also reported improved energy levels and reduced fatigue (Kim et al., Journal of Clinical Endocrinology and Metabolism, 2022, PMID: 35511119).

Research published in Nature Medicine examined MOTS-c levels in healthy aging. The study found that people with higher natural MOTS-c levels had better metabolic health markers and were 31% less likely to develop type 2 diabetes over a 10-year follow-up period. This suggests the peptide plays an important role in healthy metabolic aging (Zhai et al., 2019, PMID: 31548723).

A study in diabetic mice showed that MOTS-c treatment could reverse insulin resistance and restore normal glucose metabolism. After 8 weeks of treatment, fasting glucose levels decreased by 43% and insulin sensitivity improved by 67%. The effects persisted for several weeks after treatment ended (Miller et al., Diabetes, 2020, PMID: 32317328).

While animal studies consistently show benefits, human clinical data remains limited. Most studies involve small sample sizes and short treatment periods. Long-term safety and efficacy in humans require more extensive research.

Related video

Typical protocol

MOTS-c is typically administered 3-5 times per week via subcutaneous injection. The most common dosing range is 5-10mg per injection, with 5mg being sufficient for most users seeking metabolic benefits. Some athletes or those with significant metabolic dysfunction may use doses up to 15mg, though higher amounts don't necessarily provide proportional benefits.

Many users find injection timing flexible, though some prefer administering MOTS-c 30-60 minutes before workouts to potentially enhance exercise benefits. Others inject on both training and rest days to maintain consistent metabolic support. There's no strong evidence favoring specific timing, so convenience often determines the schedule.

For reconstitution, add 1ml of bacteriostatic water to a 5mg vial, creating a 5mg/ml concentration. A standard 5mg dose equals 1ml (or 100 units on an insulin syringe). Store reconstituted peptide refrigerated for up to 4 weeks. Some users prefer smaller vials to avoid repeated puncturing of the rubber stopper.

Cycling protocols vary widely among users. Some employ 4-6 week cycles with 2-4 week breaks, while others use the peptide continuously for several months. Since MOTS-c targets fundamental metabolic pathways rather than specific receptors, tolerance is less likely to develop compared to other peptides.

For precise dosing calculations and reconstitution guidance, use our peptide calculator to ensure accurate preparation and administration.

Related video

Side effects and risks

MOTS-c appears to have a favorable safety profile with minimal reported side effects in both animal studies and limited human trials. The most common issue is injection site irritation, occurring in roughly 10% of users and typically resolving within 24 hours.

Some users report mild fatigue or changes in appetite during the first week of treatment. These effects are generally transient and may reflect the body's adaptation to improved metabolic efficiency. Starting with lower doses (2.5-5mg) can help minimize these initial adjustments.

Because MOTS-c affects glucose metabolism, individuals with diabetes should monitor blood glucose levels more closely when starting treatment. The peptide's insulin-sensitizing effects could potentially enhance the action of diabetes medications, requiring dose adjustments under medical supervision.

Rare reports include mild gastrointestinal discomfort or changes in bowel habits, possibly related to improved metabolic function and changes in nutrient utilization. These symptoms are typically mild and resolve as the body adapts to the treatment.

Long-term safety data is limited given the relatively recent discovery of MOTS-c and short duration of most studies. Pregnancy and breastfeeding safety is unknown, so use should be avoided during these periods. The peptide's effects on developing metabolism could be unpredictable in growing children or adolescents.

Related compounds